Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE SULFA versus TRIPLE SULFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE SULFA versus TRIPLE SULFA.
ILOSONE SULFA vs TRIPLE SULFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ilosone (erythromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Sulfa (sulfisoxazole) is a sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. The combination provides synergistic bacteriostatic activity.
Inhibits bacterial dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), blocking folate synthesis essential for nucleic acid production.
Each 5 mL suspension contains 250 mg erythromycin base and 600 mg sulfisoxazole; typical adult dose is 10 mL (2 tsp) every 6 hours, not to exceed 40 mL/day.
1 g orally every 12 hours for 10 days (as sulfadiazine, sulfamethazine, and sulfamerazine combination).
None Documented
None Documented
Erythromycin: 1.5-2 hours; Sulfisoxazole: 4-7 hours; clinical context: dose adjustment in renal impairment (CrCl <50 mL/min) needed for sulfisoxazole
6-12 hours (sulfadiazine 10-13h, sulfamerazine 16-24h, sulfamethazine 7-12h); prolonged in renal impairment.
Renal: 70-80% as unchanged drug and active metabolite (sulfisoxazole); Biliary: 10-15% as metabolites; Fecal: <5%
80-90% renal (glomerular filtration and tubular secretion) as unchanged drug and acetylated metabolites; 5-10% biliary/fecal.
Category C
Category C
Macrolide and Sulfonamide Antibiotic
Sulfonamide Antibiotic